Health ❯ Pharmaceuticals

Obesity Treatment

Wegovy Drug Development Weight Loss Drugs GLP-1 Drugs Weight-loss Drugs Clinical Trials Diabetes Management Weight Loss Semaglutide Market Competition Weight Loss Medications Drug Efficacy Weight Management GLP-1 Receptor Agonists Oral GLP-1 Molecule Alzheimer's Treatment GLP-1 Analogues Retatrutide Injectable Drugs Drug Market Novo Nordisk Anti-Obesity Drugs AI Integration Weight Loss Solutions Drug Sales Eli Lilly Drug GLP-1RA GLP-1 Medicines GLP-1/GIP Medications Weight-loss Medications Diabetes Treatment Injectable Medications Investigational Drugs

Lilly Says Foundayo Now Drives One-Third of New Oral GLP-1 Starts as It Breaks Ground on $6.5 Billion Houston Plant

The project seeks to lock in U.S. supply for Foundayo to meet surging demand from Medicare coverage plus planned international rollouts.

Novo Nordisk Becomes 'Novo' as CEO Launches Cultural Reset

Lilly Sues Six U.S. Firms Over Black‑Market Sales of Experimental Drug Retatrutide

Eli Lilly Pours $4.5 Billion Into Indiana Plants, Opens Genetic-Medicine Site

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

Eli Lilly’s GLP-1 Lead Faces New Pressure From Novo’s Weight-Loss Pill

Eli Lilly Picks Huntsville for $6 Billion API Plant to Supply Next-Gen Drugs